NewGenIvf Group Limited, a Cayman-based IVF services provider listed on Nasdaq as NIVF, disclosed a completed 2025 XRP exit alongside a year-end holding of about 13,000 SOL and an unrealized
NewGenIvf Group Limited, a Cayman-based IVF services provider listed on Nasdaq as NIVF, disclosed a completed 2025 XRP exit alongside a year-end holding of about 13,000 SOL and an unrealized valuation loss of roughly $1.28 million, according to Amendment No. 2 to its SEC Form F-1 filed September 10, 2026, framing the Newgenivf XRP exit as one leg of an opportunistic corporate-treasury program that ran entirely outside its core fertility business.
The disclosure lands as public companies increasingly park idle cash in digital assets, yet NewGenIvf's filing is notable for the opposite reason: it shows a company that traded aggressively across four tokens through 2025 and ended the year holding only Solana, a concentration that turned a profitable trading year into a reported net crypto loss on paper. For related coverage, see Why Is NEAR Protocol (NEAR) Price Down Today?.
NewGenIvf bought 146,432.14 XRP and sold the identical 146,432.14 XRP during the year ended December 31, 2025, leaving a year-end XRP balance of zero, per Note 8 of the company's Form F-1/A. The round-trip trade generated a realized gain of $10,849, meaning the Newgenivf XRP exit was completed at a profit, not a loss.
The filing does not disclose the dates, prices, venues or counterparties for the XRP purchases and sales, nor whether the proceeds were redeployed into other tokens. Those transaction-level details sit outside the summarized activity table, so any inference that XRP sales funded Solana buying is unsupported by the document.
XRP was one of four tokens NewGenIvf cycled through in 2025. The company bought and sold 8.77 BTC and 8.95 ETH over the year, booking realized gains of $12,569 on Bitcoin and $223 on Ethereum, with all BTC, ETH and XRP positions fully liquidated before December 31. XRP currently trades near $1.37 as of September 13, 2026, though that spot level has no bearing on the company's realized 2025 result. Ripple's own commercial footprint has kept expanding this year as it pushes deeper into Brazil payments and pursues a VASP license, a backdrop unrelated to NewGenIvf's passive trading.
At December 31, 2025, NewGenIvf held 13,000.23 SOL, the only crypto position remaining on its balance sheet at year-end, according to the same filing. The activity table shows purchases of 46,118.55 SOL and sales of 33,118.32 SOL across 2025, netting to the reported year-end holding.
The year-end SOL carried a cost basis of $2,906,222 and a fair value of $1,630,827, with the filing noting the assets were not subject to any contractual sale restrictions, pledges or lock-up arrangements as of that date, a detail Bitcoin.com's coverage of the filing did not address.
NewGenIvf SOL holdings at December 31, 2025
13,000.23 SOL
Year-end SOL cost basis was $2,906,222 and fair value was $1,630,827. XRP holdings were zero after 146,432.14 XRP were bought and sold during 2025. These balances do not establish current holdings. Source: NewGenIvf Form F-1/A, Note 8, page F-27.The 13,000.23 SOL figure is a year-end snapshot, not a current position. The filing establishes holdings only as of December 31, 2025, and provides no update through the September 2026 disclosure window, so the balance should not be read as the company's live treasury nor multiplied by today's SOL price to estimate present value. Solana trades at roughly $102.10 as of September 13, 2026, up about 0.18% on the day, with a market capitalization near $59.9 billion, context that does not confirm whether NewGenIvf still holds the tokens.
The headline loss of about $1.28 million refers to a single line: an unrealized SOL valuation loss of $1,275,395 for 2025, the gap between the token's $2,906,222 cost and $1,630,827 year-end fair value. It is a mark-to-market paper loss, not a realized cash loss and not attributable to the XRP exit.
NewGenIvf unrealized SOL loss for 2025
$1,275,395
The approximately $1.28 million loss was an unrealized SOL valuation loss. Total realized crypto gains of $942,915 reduced the net crypto loss to $332,480. XRP trading generated a $10,849 realized gain. Source: NewGenIvf Form F-1/A, Note 8, page F-27.Netting matters here. Total realized crypto gains reached $942,915 across the four tokens, so once the unrealized SOL markdown is applied, the company recorded a net crypto loss of $332,480 within other income (expense), net, according to the filing. On Solana alone, realized gains of $919,720 were more than offset by the valuation loss, leaving a $355,675 net SOL loss for the year.
The accounting drives the optics. NewGenIvf applies ASC 350-60, remeasuring crypto assets at fair value each period with changes flowing through net income, using ASC 820 quoted active-market prices, which forces any year-end drawdown in an unsold token straight onto the income statement. That treatment is why a trading year with nearly $943,000 in realized gains still reports a loss, a dynamic that also shapes how corporate treasuries such as Bitmine's large Ethereum accumulation will surface in future filings.
The company states its core business remains IVF services, that crypto activity falls outside core operations, and that it does not engage in mining, staking, lending or other yield-generating crypto activities. The filing is a registration document, not an SEC enforcement action or endorsement, and its balances were current only as of December 31, 2025.
Unresolved from the public record: whether NewGenIvf still holds the 13,000.23 SOL after year-end, the execution dates and prices behind the XRP round-trip, and any post-2025 trading. One unconfirmed report claimed the company still held exactly that SOL balance on the research date, but that is unverified and the filing itself supports only the year-end figure. Corporate crypto strategies can also reverse quickly, as seen when Bitcoin Suisse moved to cut staff amid shifting conditions, underscoring why a nine-month-old snapshot should not be treated as live.
Did NewGenIvf exit XRP? Yes. The filing shows it bought and sold 146,432.14 XRP during 2025, ending the year with zero XRP and a $10,849 realized gain on the position.
How much SOL did NewGenIvf report holding? Roughly 13,000 SOL, specifically 13,000.23, as of December 31, 2025. The filing does not confirm whether that balance still stands, and Solana broader ecosystem activity, such as tokenized equities like FLWS going live on Solana, is unrelated to the company's holding.
Were the losses caused by the XRP exit? No. The roughly $1.28 million loss was an unrealized Solana valuation markdown; XRP trading was profitable, and the company's overall net crypto loss for 2025 was $332,480 after realized gains.
What should readers watch next? The concrete trigger is NewGenIvf's next SEC filing, which would reveal any post-year-end changes to the SOL position and whether continued fair-value remeasurement under ASC 350-60 swings the crypto line back to a gain or deepens the loss.
Disclaimer: This article is for informational purposes only and does not constitute financial or investment advice. Cryptocurrency and digital asset markets carry significant risk. Always do your own research before making decisions.
The post Newgenivf Exits XRP, Holds About 13,000 SOL; Losses Near $1.28M was initially published on Coincu.
